Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) have been assigned an average recommendation of “Hold” from the eleven research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $24.14.

Several analysts have issued reports on ITCI shares. Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th. Leerink Swann reaffirmed an “outperform” rating on shares of Intra-Cellular Therapies in a report on Monday, March 20th. Piper Jaffray Companies downgraded shares of Intra-Cellular Therapies from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $22.00 to $10.00 in a report on Monday, May 1st. Cantor Fitzgerald set a $29.00 price target on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a report on Thursday, May 11th. Finally, Ladenburg Thalmann Financial Services downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “neutral” rating in a report on Tuesday, May 2nd.

Intra-Cellular Therapies (NASDAQ ITCI) traded down 3.27% during trading on Monday, hitting $11.85. The company had a trading volume of 186,131 shares. The stock’s market capitalization is $514.53 million. Intra-Cellular Therapies has a 52-week low of $7.85 and a 52-week high of $45.20. The firm’s 50 day moving average is $10.83 and its 200-day moving average is $13.28.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.12. Intra-Cellular Therapies had a negative net margin of 27,180.94% and a negative return on equity of 29.74%. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.02 million. During the same period in the prior year, the business posted ($0.64) earnings per share. On average, equities analysts forecast that Intra-Cellular Therapies will post ($3.03) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Given Consensus Recommendation of “Hold” by Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/07/10/intra-cellular-therapies-inc-nasdaqitci-given-consensus-recommendation-of-hold-by-analysts.html.

A number of institutional investors have recently bought and sold shares of the company. State Street Corp increased its position in Intra-Cellular Therapies by 18.0% in the fourth quarter. State Street Corp now owns 972,868 shares of the biopharmaceutical company’s stock worth $14,686,000 after buying an additional 148,745 shares in the last quarter. Highbridge Capital Management LLC bought a new position in Intra-Cellular Therapies during the fourth quarter worth $166,000. Franklin Street Advisors Inc. NC increased its position in Intra-Cellular Therapies by 135.6% in the first quarter. Franklin Street Advisors Inc. NC now owns 26,060 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 15,000 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Intra-Cellular Therapies during the fourth quarter worth $574,000. Finally, Norges Bank bought a new position in Intra-Cellular Therapies during the fourth quarter worth $4,238,000. 67.55% of the stock is currently owned by institutional investors.

About Intra-Cellular Therapies

ITI Inc is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.